Plain-English translation of NCT06269146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called pramipexole can help people with anxiety or depression feel more motivated to connect with others socially. Pramipexole works by increasing dopamine signaling in the brain—a chemical thought to be involved in how we experience reward from social interactions. Researchers want to see if boosting this brain system could help people who feel socially disconnected.
Many people with anxiety or depression struggle to feel motivated to reach out to others or enjoy social time, even when they want to. This medication could offer a new way to treat social disconnection by working on a specific brain pathway related to social reward.
You likely qualify if…
You likely don't qualify if…
You would take the medication (or placebo) twice daily in capsule form for 6 weeks. At the beginning and end of the study, you'd complete brain imaging scans and answer questions about how you feel around social situations. You'll be randomly assigned to receive one of two doses of the medication or a placebo—neither you nor the researchers will know which one you're getting until the study ends.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States